<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018834</url>
  </required_header>
  <id_info>
    <org_study_id>P150921</org_study_id>
    <secondary_id>2016-003433-20</secondary_id>
    <nct_id>NCT03018834</nct_id>
  </id_info>
  <brief_title>Anakinra Versus Placebo for the Treatment of Acute MyocarditIS</brief_title>
  <acronym>ARAMIS</acronym>
  <official_title>Anakinra Versus Placebo Double Blind Randomized Controlled Trial for the Treatment of Acute MyocarditIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no specific treatment of acute myocarditis, especially during the inflammatory
      period. Interleukin (IL) is specifically involved during this period and play a role in
      myocardial oedema. ANAKINRA, an IL-1β Blocker, is a new treatment that has never been
      evaluated in myocarditis. The benefit for the patient could be important with a reduction of
      heart failure and ventricular arrhythmias.

      Hypothesis : ANAKINRA in addition to standard therapy for treatment of Acute Myocarditis is
      superior to standard therapy based on an association of beta-blockers and
      Angiotensin-Converting-Enzyme inhibitor (ACE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a Double Blind Randomized clinical trial Phase IIb of superiority, enrolling two
      groups: one group treated with the standard of care, defined as the maximum tolerated dosage
      of any beta blockers and ACE, and placebo versus ANAKINRA in addition to the standard of care
      in patients treated for an acute Myocarditis.

      Patients will be randomized to receive ANAKINRA 100 mg/daily or placebo subcutaneously once a
      day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and
      Beta-blocker for 6 months. Randomization 1:1 will be conducted centrally using the electronic
      Case Report Form (eCRF).

      As an exploratory analysis, a second randomization for ACE discontinuation in patients
      without left ventricular dysfunction (LVEF &gt; 50%) at one month post discharge will be
      performed.

      One group will stopped the treatment at one month and the second group will continued the ACE
      for 6 months. This second randomization is in open label.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days alive free of any myocarditis complications</measure>
    <time_frame>within 28 days post hospitalization</time_frame>
    <description>Number of days alive free of any myocarditis complications defined as ventricular arrhythmias, heart failure, chest pain, ventricular dysfunction defined as LVEF&lt;50%, within 28 days post hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cost</measure>
    <time_frame>on average 14 days</time_frame>
    <description>Total cost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Quality Adjusted Life Year (QALYs),</measure>
    <time_frame>on average 14 days</time_frame>
    <description>measure of the perceived utility by patients of a medication (Anakinra) that corresponds to a year of life gained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental cost effectiveness</measure>
    <time_frame>on average 14 days</time_frame>
    <description>cost-effectiveness of ANAKINRA in the setting of acute myocarditis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost utility ratios</measure>
    <time_frame>on average 14 days</time_frame>
    <description>Cost utility ratios</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricul Ejection Fraction (LVEF) assessed by cardiac Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>at 6 month</time_frame>
    <description>Left Ventricul Ejection Fraction (LVEF) assessed by cardiac Magnetic Resonance Imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricul Ejection Fraction (LVEF) assessed by Trans Thoracic Echocardiograhy (TTE)</measure>
    <time_frame>at 6 month</time_frame>
    <description>Left Ventricul Ejection Fraction (LVEF) assessed by Trans Thoracic Echocardiograhy (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF assessed by cardiac MRI</measure>
    <time_frame>at 1 year</time_frame>
    <description>LVEF assessed by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF assessed by cardiac TTE</measure>
    <time_frame>at 1 year</time_frame>
    <description>LVEF assessed by cardiac TTE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause of death rate</measure>
    <time_frame>during the 12 months follow-up</time_frame>
    <description>All cause of death rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>at 12 months</time_frame>
    <description>Cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure</measure>
    <time_frame>at 12 months</time_frame>
    <description>Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular tachycardia</measure>
    <time_frame>during the 12 months follow-up</time_frame>
    <description>Ventricular tachycardia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years) 50% decrease of the troponin level at discharge compared to admission</measure>
    <time_frame>at Day0</time_frame>
    <description>NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years) 50% decrease of the troponin level at discharge compared to admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years) 50% decrease of the troponin level at discharge compared to admission</measure>
    <time_frame>an average of 14 days</time_frame>
    <description>NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Myocarditis</condition>
  <arm_group>
    <arm_group_label>A: ANAKINRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANAKINRA 100 mg/daily subcutaneously</intervention_name>
    <description>ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.</description>
    <arm_group_label>A: ANAKINRA</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.</description>
    <arm_group_label>B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized for Acute myocarditis defined as:

          -  Chest Pain (or modification of the ECG) AND Troponin Rise (*1.5 Normal range) AND
             Myocarditis proven by MRI in the first 72h after admission

          -  Age &gt; 18 and &lt;65 years old

          -  Accepting effective contraception during treatment duration (men and women
             childbearing potential)

          -  Signed informed consent Normal Coronary angiography or coronary CT Scan (made during
             the previous year is acceptable) (normal is defined as stenosis &lt; 50%)

        Exclusion Criteria:

          -  Active coronary disease

          -  Clinical Suspicion or proven underlying disease: systemic lupus, antiphospholipid
             antibodies, Lyme disease, trypanosomiase disease, myositis, signs of sarcoidosis,
             giant cell myocarditis, chronic inflammatory disease, tuberculosis, HIV, hepatitis B
             virus (HBV) or hepatitis C virus (HCV) infection Latex allergy

          -  Pregnancy, breastfeeding

          -  Contra-indication to ANAKINRA (known hypersensitivity to the active substance or to
             any of the excipients,

          -  neutropenia &lt; 1,5.109/L)

          -  Renal failure, Creatine Clearance (CrCl) &lt; 30 ml/min (MDRD)

          -  Asthma

          -  Malignancy or any comorbidity limiting survival or conditions predicting inability to
             complete the study

          -  History of malignancy

          -  Non Steroidian Anti Inflammatory drug within the past 14 days

          -  Anti Tumor Necrosis Factor (TNF) within the past 14 days

          -  No affiliation to the French Health Care System &quot;sécurité sociale&quot;

          -  Hepatic impairment = Child-Pugh Class C

          -  Mechanical ventilation Circulatory assistance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu KERNEIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ACTION Study Group - Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fleur COHEN AUBART, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles MONTALESCOT, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ACTION Study Group - Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu KERNEIS, MD</last_name>
    <phone>33 142 16 29 40</phone>
    <email>mathieu.kerneis@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fleur COHEN AUBART, MD</last_name>
    <phone>33 1 4217 82 42</phone>
    <email>fleur.cohen@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ACTION Study Group - Department of Cardiology - Pitié Salpétrière Hospital, 47 Bd de l'Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu KERNEIS, MD</last_name>
      <phone>33 1 42 16 29 40</phone>
      <email>mathieu.kerneis@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of internal medicine - Pitié Salpétrière Hospital, 47 Bd de l'Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fleur COHEN AUBART, MD</last_name>
      <phone>33 1 42 17 82 42</phone>
      <email>fleur.cohen@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocarditis</keyword>
  <keyword>ANAKINRA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

